2024 in pharma — approvals, patent cliffs, Phase 3 readouts

Every FDA approval, patent expiry, and pivotal Phase 3 readout tracked for 2024: 56 approvals, 63 patent expiries, 0 Phase 3 milestones.

20222023202420252026

FDA / EMA / MHRA approvals (56)

Patent expiries (63)

Phase 3 readouts (0)

No entries tracked.